Free Trial

Avadel Pharmaceuticals Q1 2024 Earnings Report

Avadel Pharmaceuticals logo
$8.01 -0.11 (-1.35%)
As of 03/28/2025 04:00 PM Eastern

Avadel Pharmaceuticals EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.25
Beat/Miss
Missed by -$0.05
One Year Ago EPS
-$0.48

Avadel Pharmaceuticals Revenue Results

Actual Revenue
$27.18 million
Expected Revenue
$25.89 million
Beat/Miss
Beat by +$1.29 million
YoY Revenue Growth
+2,617.80%

Avadel Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Avadel Pharmaceuticals Earnings Headlines

Avadel Pharmaceuticals announces publications in CNS Drugs supplement
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
See More Avadel Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avadel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avadel Pharmaceuticals and other key companies, straight to your email.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals (NASDAQ:AVDL) operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

View Avadel Pharmaceuticals Profile

More Earnings Resources from MarketBeat